Back to the RadioSpace™ home page
NewsDirect story topics:
Consumer, Business & General Interest
Current Events & Public Affairs
Entertainment & Sports
Health & Medicine
Advances in Treatment Are Helping Some Patients with Pancreatic Cancer Live Longer
Fully produced report (and fair balance) in MP3 format:
48 kbps |
96 kbps
(122 seconds)
-- How Will You Use This Story? --
(OPEN):
NEWLY RELEASED AMERICAN CANCER SOCIETY STATISTICS SHOW
THAT THE NUMBER OF AMERICANS DIAGNOSED WITH PANCREATIC CANCER--ONE OF
THE MOST-DEADLY AND -DIFFICULT-TO-TREAT CANCERS--CONTINUES TO RISE,
EVERY YEAR. THIS YEAR, AN ESTIMATED 37-THOUSAND-600 AMERICANS WILL
BE DIAGNOSED WITH--AND OVER 34-THOUSAND WILL DIE OF--PANCREATIC CANCER.
HOWEVER, A TARGETED THERAPY, IN COMBINATION WITH CHEMOTHERAPY, IS GIVING
PATIENTS, LIKE 75-YEAR-OLD LEE PHILLIPS, SOME HOPE...
(PHILLIPS):
"IT CAME AS A COMPLETE SHOCK, WHEN I WAS DIAGNOSED
WITH PANCREATIC CANCER. MY ONCOLOGISTS RECOMMEND CHEMOTHERAPY AND
A TARGETED THERAPY CALLED 'TARCEVA'--WHICH IS WORKING GREAT FOR ME.
I'M THANKFUL FOR EVERY DAY I'M GIVEN, AND FOCUS ON CONTINUING TO REMAIN
ACTIVE AND DO THE THINGS I LIKE--FOR AS LONG AS I CAN."
(CLOSE):
"TARCEVA"--"ERLOTINIB" TABLETS--TARGETS A CANCER PATHWAY IMPORTANT TO THE
DEVELOPMENT AND SPREAD OF PANCREATIC CANCER. STUDIES SHOW THAT THE
TREATMENT COMBINATION OF "TARCEVA" AND THE CHEMOTHERAPY "GEMCITABINE"
BUILDS ON THE STANDARD OF CARE--AND MAY HELP SOME PATIENTS WITH
PANCREATIC CANCER LIVE LONGER.
-- FAIR BALANCE
--
EACH PATIENT IS UNIQUE--AND RESULTS WITH "TARCEVA" MAY VARY. "TARCEVA"
IS AN ORAL TABLET APPROVED FOR USE IN COMBINATION WITH "GEMCITABINE" FOR THE
FIRST-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR
METASTATIC PANCREATIC CANCER. THERE HAVE BEEN INFREQUENT REPORTS OF
INTERSTITIAL-LUNG-DISEASE (I-L-D)-LIKE EVENTS--INCLUDING FATALITIES--IN
PATIENTS RECEIVING "TARCEVA". IN PATIENTS RECEIVING "TARCEVA" PLUS
"GEMCITABINE", MYOCARDIAL INFARCTION/ISCHEMIA, CEREBROVASCULAR ACCIDENT, AND
MICRO-ANGIOPATHIC HEMOLYTIC ANEMIA WITH THROMBOCYTOPENIA HAVE OCCURRED.
WHILE RECEIVING "TARCEVA" THERAPY, WOMEN SHOULD BE ADVISED AGAINST BECOMING
PREGNANT OR BREASTFEEDING. THE MOST-COMMON SIDE EFFECTS IN PATIENTS
WITH PANCREATIC CANCER RECEIVING "TARCEVA" WERE FATIGUE, RASH, NAUSEA,
ANOREXIA, AND DIARRHEA. FOR MORE INFORMATION, VISIT THE PANCREATIC
CANCER ACTION NETWORK AT
W-W-W-DOT-"PAN-CAN"-DOT-ORG--OR CALL 877-272-6226. FOR MORE
INFORMATION ABOUT "TARCEVA", PLEASE VISIT
W-W-W-DOT-"TARCEVA"-DOT-COM.
